Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

President Trump said in a new video on Wednesday evening that contracting the coronavirus was "a blessing in disguise" and claimed — without scientific evidence — that the antibody cocktail from Regeneron Pharmaceuticals he was treated with is a "cure."

Driving the news: The president said he is seeking emergency use authorization for the antibody cocktail, which he received last week while experiencing "mild" symptoms. He claimed that it was his suggestion to doctors that he be treated with the therapeutic, which Regeneron says has only been given to fewer than 10 people outside of clinical trials.

What he's saying: "I spent four days at [Walter Reed]," Trump said. "I went in and I wasn't feeling so hot. And within a very short period of time, they gave me Regeneron. It's called Regeneron. And other things too, but I think this was the key."

  • "They gave me Regeneron, and it was like unbelievable. I felt good immediately. I felt as good three days ago as I do now. So I just want to say, we have Regeneron. We have another drug by [Eli Lilly and Company]. And they're coming out, and we're trying to get them on an emergency basis."
  • "We've authorized it. I've authorized it. And if you're in the hospital and you're feeling really bad, I think we're going to work it to where you're going to get them and you're going to get them free. And especially if you're a senior, we're going to get you in there quick."
  • "They call them therapeutic, but to me, it wasn't therapeutic. It just made me better. Okay, I call that a cure."

Go deeper: White House physician says Trump has been "symptom-free for over 24 hours"

Go deeper

Oct 11, 2020 - Health

Ex-FDA chief: Trump "definitely missed the window" to mass produce antibody drug

The Trump administration "definitely missed the window" to mass produce Regeneron Pharmaceuticals' coronavirus antibody drug this year, former FDA commissioner Scott Gottlieb told CBS News' "Face the Nation" on Sunday.

Why it matters: President Trump, who received the antibody cocktail after testing positive for the coronavirus, has hailed the drug as a miraculous "cure" — despite a lack of scientific evidence — and promised to distribute it to every hospital for free.

Updated 3 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Annelise Capossela/Axios

1 hour ago - Health

Treasury begins dispersing $350 billion in COVID relief funding to states and localities

Treasury Secretary Janet Yellen. Photo: Tasos Katopodis/UPI/Bloomberg via Getty Images

The U.S. Treasury on Monday began giving state and local governments access to $350 billion in emergency funding from the American Rescue Plan, the department announced Monday.

Why it matters: Though the money is aimed at helping state, local, territorial and tribal governments recover from the pandemic's economic fallout, the administration will generally give them wide latitude on how they can use the funds.

You’ve caught up. Now what?

Sign up for Mike Allen’s daily Axios AM and PM newsletters to get smarter, faster on the news that matters.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!